Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pacira BioSciences, Inc. (NASDAQ: PCRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, along with AI-powered tools to help interpret complex documents. Pacira is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its filings give detailed insight into how it manages product commercialization, manufacturing, financing and governance.
Pacira’s current reports on Form 8‑K cover topics such as quarterly financial results, workforce reductions tied to manufacturing efficiencies for EXPAREL, and a senior secured revolving credit facility used to refinance prior indebtedness and support working capital. One 8‑K describes the company’s investment in large-scale manufacturing suites in San Diego, California, and Swindon, United Kingdom, and the decision to decommission an earlier 45‑liter batch suite, while another outlines the terms of its credit agreement with lenders.
Investors reviewing Pacira’s filings typically focus on annual reports on Form 10‑K and quarterly reports on Form 10‑Q for information about its commercial products—EXPAREL, ZILRETTA and iovera°—and its clinical-stage gene therapy candidate PCRX-201. These filings generally discuss revenue composition, research and development activities, manufacturing capacity, risk factors and intellectual property, including patent protection for EXPAREL described in company press releases.
Forms 8‑K also document material events such as share repurchase authorizations, inducement equity grants under the company’s inducement plan, credit facility amendments and other significant corporate actions. For users interested in insider activity, Forms 3, 4 and 5 provide data on transactions by directors, officers and major shareholders, while proxy statements explain executive compensation and board matters.
On Stock Titan, AI-generated summaries help explain lengthy filings, highlight key changes from prior periods and surface items that may affect Pacira’s financial position or strategy. Real-time updates from EDGAR ensure that new 10‑K, 10‑Q, 8‑K and Form 4 filings for PCRX are quickly available, allowing investors to track developments in Pacira’s non-opioid pain portfolio, manufacturing initiatives and capital structure without reading every page manually.
Pacira BioSciences director Bigal Marcelo reported a sale of 4,912 shares of common stock at $23.67 per share on 08/07/2025, reducing his direct holding to 11,393 shares. The Form 4 discloses no derivative transactions. The filing documents an insider sale and the remaining direct beneficial ownership reported by the director.
This Schedule 13D discloses that Doma Perpetual-related entities, Pedro Escudero and the John Templeton Foundation together beneficially own 2,698,618 common shares of Pacira BioSciences, representing 5.7% of 47,432,721 outstanding shares as of 8/5/2025. Doma Master Fund accumulated 1,804,069 shares in 2023–Q1 2025 for an aggregate purchase price of $48,257,894; Mr. Escudero bought 159,000 shares in Q3 2024 for $3,256,514; the John Templeton Foundation purchased 735,549 shares on 8/1, 8/4 and 8/5/2025 for $16,329,100.
The reporting persons state the shares were acquired "with the intent to influence the Issuer" but not to take full control. They say they are not currently pursuing a merger, management or operational changes, though they may contemplate such actions if the Common Shares are deemed to be underperforming. The filing includes no contracts or exhibits describing specific plans.
Pacira BioSciences (PCRX) filed an 8-K on 9 July 2025 announcing a restructuring under Item 2.05. The company is shuttering its first-generation 45-liter manufacturing suite at its San Diego Science Center after commissioning two 200-plus-liter suites (Swindon 2021, San Diego 2024) that produce roughly 4× more bulk EXPAREL per batch and carry a lower cost structure.
The decision triggers a reduction in force of 71 employees, or ~8 % of head-count. Management expects to book $2.4 – $2.8 million in cash charges for severance, garden leave and related benefits plus $5.4 million of accelerated depreciation, with most of the impact flowing through Q3 2025 results.
Once complete, Pacira anticipates an annual operating-expense reduction of about $13 million and improved gross margins for EXPAREL owing to higher yields and scale efficiencies. The company cautions that additional, presently unforeseen, charges may arise and reiterates standard forward-looking-statement language.
An employee communication from CEO Frank D. Lee (Exhibit 99.1) was furnished under Item 7.01 and is not deemed filed. No changes were disclosed to current revenue guidance, product strategy or other financial metrics beyond the charges and cost-saving estimates.